BNP Paribas Financial Markets Purchases 16,597 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

BNP Paribas Financial Markets increased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 448.9% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 20,294 shares of the company's stock after acquiring an additional 16,597 shares during the quarter. BNP Paribas Financial Markets' holdings in Protagonist Therapeutics were worth $913,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Farallon Capital Management LLC increased its stake in Protagonist Therapeutics by 1.8% in the 2nd quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company's stock worth $202,383,000 after acquiring an additional 101,800 shares during the last quarter. Pacer Advisors Inc. grew its holdings in shares of Protagonist Therapeutics by 405,061.2% during the third quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company's stock worth $78,034,000 after purchasing an additional 1,733,662 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Protagonist Therapeutics by 27.6% in the second quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company's stock worth $43,962,000 after purchasing an additional 274,412 shares during the last quarter. Millennium Management LLC raised its stake in Protagonist Therapeutics by 2,135.6% in the second quarter. Millennium Management LLC now owns 958,283 shares of the company's stock valued at $33,205,000 after purchasing an additional 915,418 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Protagonist Therapeutics by 7.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 565,503 shares of the company's stock valued at $25,448,000 after purchasing an additional 39,850 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company's stock.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CEO Dinesh V. Ph D. Patel sold 78,520 shares of the business's stock in a transaction on Monday, November 25th. The shares were sold at an average price of $46.96, for a total transaction of $3,687,299.20. Following the transaction, the chief executive officer now directly owns 435,208 shares of the company's stock, valued at approximately $20,437,367.68. The trade was a 15.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Arturo Md Molina sold 1,906 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the completion of the sale, the insider now directly owns 46,444 shares of the company's stock, valued at approximately $1,903,275.12. This represents a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 209,863 shares of company stock worth $9,689,847. 5.40% of the stock is currently owned by insiders.

Protagonist Therapeutics Stock Performance

PTGX stock traded down $0.62 during trading on Thursday, hitting $40.38. 584,351 shares of the company traded hands, compared to its average volume of 744,118. The company has a 50-day moving average of $44.53 and a 200-day moving average of $40.40. Protagonist Therapeutics, Inc. has a 1 year low of $19.16 and a 1 year high of $48.89. The firm has a market capitalization of $2.41 billion, a PE ratio of 15.41 and a beta of 2.18.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on PTGX shares. StockNews.com lowered shares of Protagonist Therapeutics from a "buy" rating to a "hold" rating in a report on Tuesday. TD Cowen upgraded Protagonist Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 25th. Truist Financial began coverage on Protagonist Therapeutics in a report on Monday, September 9th. They issued a "buy" rating and a $60.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday. Finally, The Goldman Sachs Group began coverage on Protagonist Therapeutics in a research report on Friday, December 6th. They issued a "neutral" rating and a $47.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $53.78.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.